Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
With Novo Nordisk’s GLP-1 drug Ozempic (semaglutide) on its tail, Eli Lilly has rounded up some mid-stage data to show it has the right candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
